Digital healthcare company Humanscape (CEO Jang Min-hoo) announced on the 22nd that it has signed a strategic partnership with the Korea Rare and Incurable Disease Association (Chairman Kim Jae-hak, hereinafter KORD) to improve the treatment environment for domestic rare disease patients and expand access to new drugs.
This collaboration focuses on the introduction of a drug cost assistance program to alleviate the burden on patients who discontinue treatment for financial reasons. This public service initiative aims to support patients with rare diseases requiring expensive treatments, enabling them to continue their treatment in a stable manner.
The two companies have been working together since 2022, and as part of Hana Financial Group's ESG initiative, they jointly promoted the "Patient-Driven Health Data Construction Project." This project confirmed the potential of patient-centered health data to play a crucial role in overcoming rare diseases.
Humanscape is digitally transforming its drug reimbursement and medication adherence management programs, leveraging its "RareNote" app, a comprehensive platform for rare diseases. This process will streamline existing paper-based procedures and improve the user experience, enabling patients to more easily apply for and manage support through the app.
KORD, as a public interest organization, will provide reliable patient support services and, in the future, collaborate to create a patient-centered treatment environment by developing various customized programs.
Kim Jae-hak, Chairman of KORD, said, “This collaboration will be an opportunity to bring about changes in the way the association operates its business,” and added, “We will increase patient accessibility through digital-based services and contribute to improving the treatment environment for rare diseases based on the collected data.”
“Data containing patient voices is a key asset in responding to rare diseases,” said Jang Min-hu, CEO of Humanscape. “We will utilize digital technology to eliminate treatment blind spots and expand opportunities for patient-led treatment.”
- See more related articles
You must be logged in to post a comment.